◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › T › TLRY

Tilray Inc (TLRY) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-11-04

Tilray Inc (TLRY) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Leamington, Canada with about 3,595 employees. Its market capitalization is roughly $392 million. In the fiscal year ended 2026-05-31, TLRY reported $915M in revenue and ($123M) in net income.

Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally.

Interactive charts & full statements → Open the TLRY valuation workbench →

TLRY Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-08-31	2026-05-31	2025-05-31	2024-05-31	2023-05-31	2022-05-31	2021-05-31	2020-05-31	2019-05-31	2018-05-31	2017-05-31	2016-05-31	2015-05-31	2014-05-31	2013-05-31	2012-05-31
Total Revenue	$963M	$915M	$1.1B	$1.1B	$845M	$628M	$513M	$405M	$43M	$21M	$15M	$6M	$0M	—	—	—
Gross Profit	$280M	$260M	$330M	$304M	$198M	$117M	$123M	—	$32M	$24M	$13M	$4M	$1M	$0M	—	—
Gross Margin %	29.1%	28.4%	29.3%	28.3%	23.4%	18.6%	24.0%	23.7%	74.7%	119.2%	84.6%	54.6%	144.1%	—	—	—
Operating Income (EBIT)	($89M)	($63M)	($3.1B)	($238M)	($1.8B)	($233M)	($132M)	($76M)	($37M)	($7M)	($1M)	($1M)	($2M)	($1M)	$0M	$0M
Operating Margin %	-9.2%	-6.9%	-277.9%	-22.1%	-218.4%	-37.1%	-25.8%	-25.7%	-85.0%	-36.5%	-6.8%	-12.9%	-615.8%	—	—	—
Net Income	($164M)	($123M)	($3.0B)	($334M)	($2.0B)	($477M)	($367M)	($75M)	($68M)	($8M)	$3M	$0M	($4M)	($1M)	$0M	$0M
Net Margin %	-17.0%	-13.4%	-266.2%	-31.1%	-231.6%	-75.9%	-71.6%	-25.3%	-157.0%	-38.0%	20.5%	4.7%	-1186.6%	—	—	—
EBITDA	—	($39M)	($2.9B)	($99M)	($1.7B)	($246M)	($246M)	($35M)	($11M)	$26M	$5M	$0M	($4M)	($1M)	$0M	$0M
Earnings Per Share (EPS)	—	$-1.10	$-33.70	$-4.49	$-31.66	$-9.91	$-13.63	$-3.27	$-3.33	$-0.56	$0.33	$0.06	$-1.11	$-0.06	$-0.01	$-0.29
Shares Outstanding (M)	—	112M	89M	74M	62M	48M	27M	23M	20M	14M	9M	5M	—	—	3M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TLRY Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-08-31	2026-05-31	2026-02-28	2025-11-30	2025-08-31	2025-05-31	2025-02-28	2024-11-30	2024-08-31
Total Revenue	$257M	$282M	$282M	$304M	$288M	$308M	$268M	$295M	$270M
Gross Profit	$78M	$84M	$75M	$80M	$79M	$93M	$75M	$86M	$81M
Gross Margin %	30.3%	29.9%	26.6%	26.4%	27.4%	30.1%	28.0%	29.0%	29.8%
Operating Income (EBIT)	—	($4M)	($27M)	($31M)	$3M	($2.0B)	($1.1B)	($59M)	($49M)
Operating Margin %	—	-1.6%	-9.6%	-10.2%	1.0%	-643.1%	-409.0%	-20.0%	-18.3%
Net Income	($43M)	($50M)	($36M)	($63M)	$0M	($1.7B)	($1.1B)	($119M)	($53M)
Net Margin %	-16.7%	-17.6%	-12.8%	-20.7%	-0.1%	-566.9%	-424.9%	-40.5%	-19.6%
EBITDA	—	$15M	($2M)	($26M)	$30M	($1.8B)	($1.1B)	($58M)	$11M
Earnings Per Share (EPS)	$-0.32	$-0.44	$-0.32	$-0.57	$-0.00	$-17.86	$-12.55	$-1.38	$-0.60
Shares Outstanding (M)	—	112M	113M	110M	106M	98M	91M	86M	88M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TLRY Free Cash Flow History

Cash flow	TTM → 2026-08-31	2026-05-31	2025-05-31	2024-05-31	2023-05-31	2022-05-31	2021-05-31	2020-05-31	2019-05-31	2018-05-31	2017-05-31	2016-05-31	2015-05-31	2014-05-31	2013-05-31	2012-05-31
Cash from Operations (CFO)	($84M)	($69M)	($130M)	($42M)	$8M	($177M)	($54M)	($250M)	($47M)	($6M)	($4M)	($1M)	($4M)	$0M	($1M)	$0M
Capital Expenditures (CapEx)	$34M	$33M	$45M	$40M	$21M	$34M	$47M	$71M	$51M	$11M	$1M	$3M	$2M	$0M	$0M	$0M
Free Cash Flow (FCF)	($119M)	($102M)	($175M)	($82M)	($13M)	($211M)	($101M)	($322M)	($97M)	($17M)	($5M)	($3M)	($5M)	$0M	($1M)	$0M
FCF Margin %	-12.4%	-11.2%	-15.5%	-7.6%	-1.5%	-33.6%	-19.7%	-109.0%	-225.4%	-80.8%	-33.9%	-50.0%	-1442.8%	—	—	—
Dividends Paid	—	—	$2M	—	$81M	$7.5B	—	—	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TLRY Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-08-31	2026-05-31	2026-02-28	2025-11-30	2025-08-31	2025-05-31	2025-02-28	2024-11-30	2024-08-31
Cash from Operations (CFO)	($16M)	($37M)	($22M)	($12M)	($2M)	($20M)	($5M)	($57M)	($48M)
Capital Expenditures (CapEx)	$11M	$10M	$4M	$14M	$13M	$9M	$20M	$8M	$9M
Free Cash Flow (FCF)	($28M)	($48M)	($26M)	($25M)	($15M)	($29M)	($25M)	($64M)	($57M)
FCF Margin %	-10.9%	-16.9%	-9.2%	-8.4%	-5.2%	-9.5%	-9.2%	-21.8%	-21.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

TLRY Balance Sheet History

Balance sheet	2026-05-31	2026-05-31	2025-05-31	2024-05-31	2023-05-31	2022-05-31	2021-05-31	2020-05-31	2019-05-31	2018-05-31	2017-05-31	2016-05-31	2015-05-31	2014-05-31	2013-05-31	2012-05-31
Total Assets	$2.3B	$2.3B	$2.9B	$5.9B	$5.9B	$6.9B	$6.0B	$869M	$662M	$53M	$45M	$21M	$9M	$0M	$0M	$0M
Cash & Cash Equivalents	$226M	$226M	$304M	$311M	$278M	$524M	$488M	$94M	$491M	$2M	$10M	$10M	$5M	$0M	$0M	$0M
Total Liabilities	$733M	$733M	$860M	$1.2B	$1.4B	$1.3B	$1.6B	$592M	$463M	$58M	$41M	$1M	$1M	$0M	$0M	$0M
Total Debt (Short + Long-Term)	$240M	$240M	$275M	$341M	$660M	$637M	$885M	$294M	$0M	$42M	$27M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$1.6B	$1.6B	$2.1B	$4.7B	$4.5B	$5.5B	$4.5B	$277M	$199M	($5M)	$3M	$21M	$9M	$0M	$0M	$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TLRY viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

AQST · Aquestive Therapeutics Inc — $487 million
EOLS · Evolus Inc — $487 million
TKNO · Alpha Teknova Inc — $454 million
KMDA · Kamada — $444 million
CGC · Canopy Growth Corp — $293 million
BIOA · BioAge Labs, Inc — $269 million
GLAS · Glass House Brands Inc. — $221 million
TAK · Takeda Pharmaceutical Co Ltd ADR — $66 billion

← TLPH All “T” companies TLS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.